Provided by Tiger Trade Technology Pte. Ltd.

Palisade Bio Inc.

1.93
+0.190010.92%
Volume:3.48M
Turnover:6.46M
Market Cap:287.57M
PE:-0.83
High:1.95
Open:1.74
Low:1.74
Close:1.74
52wk High:2.64
52wk Low:0.5300
Shares:149.00M
Float Shares:105.00M
Volume Ratio:1.95
T/O Rate:3.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3306
EPS(LYR):-10.1929
ROE:-228.64%
ROA:-87.81%
PB:89.59
PE(LYR):-0.19

Loading ...

BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec

Reuters
·
Dec 02, 2025

Palisade Bio Strengthens Clinical Leadership Team With Appointment of James Izanec, Md, Agaf as Vice President, Clinical Development

THOMSON REUTERS
·
Dec 02, 2025

Palisade Bio price target raised to $8 from $2 at Maxim

TIPRANKS
·
Nov 12, 2025

Palisade Bio Inc expected to post a loss of 27 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Oct 29, 2025

BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical Operations

Reuters
·
Oct 28, 2025

Palisade Bio Inc. held annual shareholder meeting

Reuters
·
Oct 21, 2025

Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Oct 20, 2025

BRIEF-Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

Reuters
·
Oct 20, 2025

Palisade Bio Inc - Data to Support Phase 2 Ind Submissions to FDA in H1 2026

THOMSON REUTERS
·
Oct 20, 2025

Palisade Bio Inc - Topline Data for Pali-2108 Study Expected in Q1 2026

THOMSON REUTERS
·
Oct 20, 2025

Palisade Bio Announces First Patients Dosed in Phase 1B Study of Oral First-in-Class Pde4 Inhibitor Prodrug, Pali-2108, for the Treatment of Fibrostenotic Crohn’s Disease (Fscd)

THOMSON REUTERS
·
Oct 20, 2025

Palisade Bio granted Canadian patent covering PALI-2108 composition

TIPRANKS
·
Oct 13, 2025

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

GlobeNewswire
·
Oct 13, 2025

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

Benzinga_recent_news
·
Oct 08, 2025

Palisade Bio Closes $138 Million Public Offering

MT Newswires Live
·
Oct 03, 2025

Palisade Bio Prices Upsized $120 Million Underwritten Public Offering; Shares Rise

MT Newswires Live
·
Oct 01, 2025

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
Oct 01, 2025

BRIEF-Palisade Bio Announces Adjournment Of Special Meeting Of Stockholders Due To Lack Of Quorum

Reuters
·
Sep 27, 2025

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

THOMSON REUTERS
·
Sep 27, 2025